Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. Year to date metric has recorded a loss of -97.77%.However, over the last six months, we can see a stronger performance of -97.77%. Over the last 30 days, the price of SLXN has leaped by -54.69%. And in the last five days, it has fallen by -21.10%.
The market performance of Silexion Therapeutics Corp has been somewhat unstable.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
52-week price history of SLXN Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. Silexion Therapeutics Corp’s current trading price is -98.22% away from its 52-week high, while its distance from the 52-week low is -11.03%. The stock’s price range over this timeframe has been between $0.27 and $13.56. The shares of the Healthcare sector company recorded a trading volume of approximately 1.67 million for the day, which was comparatively lower than the average daily volume of 2.75 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Silexion Therapeutics Corp (SLXN) has experienced a quarterly decline of -97.95% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.75M.
How Moving Averages and Trading Volume Data Work Together
SLXN’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for SLXN stands at 1.32. Similarly, the long-term debt-to-equity ratio is also 0.00.
SLXN Stock Stochastic Average
The raw stochastic average for Silexion Therapeutics Corp over the last 50 days is presently at 0.71%. This reflects a drop from the raw stochastic average of the previous 20 days, which was noted at 4.72%. Further, the company’s Stochastic %K and %D values for the last 20 days were 7.29% and 7.53%, respectively.
